Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
TYK2 inhibitors
15 evidence topics · 11 sources
FDA-approved indication, dosage, and pretreatment tuberculosis evaluation: deucravacitinib
Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label
| Endpoint, n (%) | SOTYKTU (N=330) | Placebo (N=166) | Apremilast (N=168) |
|---|---|---|---|
| sPGA 0/1, Week 16 | “178 (54)” | “12 (7)” | “54 (32)” |
| PASI 75, Week 16 | “193 (58)” | “21 (13)” | “59 (35)” |
| PASI 90, Week 16 | “118 (36)” | “7 (4)” | “33 (20)” |
| Endpoint at Week 24, Trial PSO-1, n (%) | SOTYKTU (N=330) | Apremilast (N=168) |
|---|---|---|
| PASI 75 | “228 (69)” | “64 (38)” |
| PASI 90 | “140 (42)” | “37 (22)” |
POETYK PSO-1: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast
“Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
POETYK PSO-2: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast
“POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, significantly more deucravacitinib-treated patients versus placebo and apremilast patients achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index (53.0% vs 9.4% and 39.8%; P < .0001 vs placebo; P = .0004 vs apremilast) and static Physician's Global Assessment score of 0 or 1 (49.5% vs 8.6% and 33.9%; P < .0001 for both).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent adverse event with deucravacitinib was nasopharyngitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events and discontinuations due to adverse events were infrequent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Randomized withdrawal: maintenance of sPGA 0 or 1 at week 52 with continued deucravacitinib versus placebo
Adverse reactions through week 16 in Trials PSO-1 and PSO-2: deucravacitinib label
| Adverse reaction, n (%) | SOTYKTU 6 mg once daily (N=840) | Placebo (N=419) |
|---|---|---|
| Upper respiratory infections | “161 (19.2)” | “62 (14.8)” |
| Blood creatine phosphokinase increased | “23 (2.7)” | “5 (1.2)” |
| Herpes simplex | “17 (2)” | “1 (0.2)” |
| Mouth ulcers | “16 (1.9)” | “0 (0.0)” |
| Folliculitis | “14 (1.7)” | “0 (0.0)” |
Warnings: infections, creatine phosphokinase elevation, triglycerides, and potential JAK inhibition risks
Continuous deucravacitinib: PASI 90 and DLQI 0/1 through 4 years
“In patients who received continuous deucravacitinib (n = 513), clinical and patient‐reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%–50.0%], 4 years, 47.5% [42.6%–52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%–55.9%], 4 years, 49.4% [44.4%–54.4%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucravacitinib exposure-adjusted safety through 5 years
“Overall, 1519 patients received one or more deucravacitinib dose; total exposure was 5046.7 PY through data cutoff (September 2, 2024).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EAIRs/100 PY were comparable or decreased from the 1-year to 5-year cumulative period for adverse events (AEs) (229.23, 127.40, respectively), serious AEs (5.68, 5.06), discontinuation due to AEs (4.38, 2.09), deaths (0.20, 0.22), serious infections excluding coronavirus disease 2019 (COVID-19) (1.53, 0.94), malignancies (1.02, 0.92), major adverse cardiovascular events (0.30, 0.34), and venous thromboembolism (0.20, 0.06).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements: deucravacitinib infections, herpes zoster, laboratory changes, and malignancies
“Deucravacitinib may increase the risk of infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the pivotal trials POETYK PSO‐1, PSO‐2 and the open‐label extension study, ten of the 18 patients reporting herpes zoster were less than 50 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled data from clinical trials on changes in laboratory findings show that treatment with deucravacitinib may result in the following changes in laboratory findings: increase of creatine kinase (from asymptomatic to rhabdomyolysis), increase of triglyceride levels and increase of liver enzymes by ≥ 3‐fold of the upper limit of normal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the pooled data from the complete treatment periods of the pivotal trials PSO‐1, PSO‐2, and the open‐label extension study (overall, 2,482 patient‐years of exposure with deucravacitinib), malignancies were reported in 22 patients (0.9 per 100 patient‐years), including eleven cases of non‐melanoma skin cancer (0.4 per 100 patient‐years) and three cases of lymphoma (0.1 per 100 patient‐years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis: deucravacitinib compared with biologics and apremilast for PASI 90
“There was evidence of a difference in favour of infliximab, anti‐IL17 agents (bimekizumab, ixekizumab, secukinumab, sonelokimab, brodalumab), and anti‐IL23 agents (risankizumab and guselkumab) compared to ustekinumab, tildrakizumab, the three anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and deucravacitinib in terms of achieving PASI 90.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib and risankizumab were more effective than apremilast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zasocitinib: phase 2b dose-ranging trial, PASI 75 at week 12
“Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Zasocitinib: LATITUDE PsO 3001 and 3002 week 16 results versus placebo and apremilast
| Endpoint at Week 16 | LATITUDE PsO 3001 | LATITUDE PsO 3002 |
|---|---|---|
| sPGA 0/1 | “71% zasocitinib vs 11% placebo and 32% apremilast (p<0.001)” | “69% zasocitinib vs 13% placebo and 30% apremilast (p<0.001)” |
| PASI 75 | “76% zasocitinib vs 12% placebo and 37% apremilast (p<0.001)” | “71% zasocitinib vs 12% placebo and 33% apremilast (p<0.001)” |